JP2017510257A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510257A5 JP2017510257A5 JP2016554603A JP2016554603A JP2017510257A5 JP 2017510257 A5 JP2017510257 A5 JP 2017510257A5 JP 2016554603 A JP2016554603 A JP 2016554603A JP 2016554603 A JP2016554603 A JP 2016554603A JP 2017510257 A5 JP2017510257 A5 JP 2017510257A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- seq
- car
- cell lymphoma
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403905A GB201403905D0 (en) | 2014-03-05 | 2014-03-05 | Method |
| GB1403905.1 | 2014-03-05 | ||
| GB1416908.0 | 2014-09-25 | ||
| GB201416908A GB201416908D0 (en) | 2014-09-25 | 2014-09-25 | Method |
| PCT/GB2015/050643 WO2015132598A1 (en) | 2014-03-05 | 2015-03-05 | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107689A Division JP6767931B2 (ja) | 2014-03-05 | 2017-05-31 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2020054667A Division JP7149304B2 (ja) | 2014-03-05 | 2020-03-25 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510257A JP2017510257A (ja) | 2017-04-13 |
| JP2017510257A5 true JP2017510257A5 (enExample) | 2018-02-22 |
| JP6767872B2 JP6767872B2 (ja) | 2020-10-14 |
Family
ID=52649058
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016554603A Active JP6767872B2 (ja) | 2014-03-05 | 2015-03-05 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2017107689A Active JP6767931B2 (ja) | 2014-03-05 | 2017-05-31 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2020054667A Active JP7149304B2 (ja) | 2014-03-05 | 2020-03-25 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2021150189A Withdrawn JP2021184773A (ja) | 2014-03-05 | 2021-09-15 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2024060080A Pending JP2024074907A (ja) | 2014-03-05 | 2024-04-03 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017107689A Active JP6767931B2 (ja) | 2014-03-05 | 2017-05-31 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2020054667A Active JP7149304B2 (ja) | 2014-03-05 | 2020-03-25 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2021150189A Withdrawn JP2021184773A (ja) | 2014-03-05 | 2021-09-15 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
| JP2024060080A Pending JP2024074907A (ja) | 2014-03-05 | 2024-04-03 | Ｔ細胞受容体ベータ定常領域に対する抗原結合ドメインを有するキメラ抗原抗体（ｃａｒ） |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20170066827A1 (enExample) |
| EP (4) | EP4736887A3 (enExample) |
| JP (5) | JP6767872B2 (enExample) |
| KR (3) | KR102088082B1 (enExample) |
| CN (4) | CN118852462A (enExample) |
| AU (3) | AU2015225944B2 (enExample) |
| BR (1) | BR112016020304B1 (enExample) |
| CA (1) | CA2940564C (enExample) |
| CL (4) | CL2016002195A1 (enExample) |
| CU (1) | CU24475B1 (enExample) |
| DK (2) | DK3125934T3 (enExample) |
| ES (2) | ES3033286T3 (enExample) |
| FI (1) | FI3241561T3 (enExample) |
| HU (2) | HUE071755T2 (enExample) |
| IL (3) | IL278879B2 (enExample) |
| MX (3) | MX2016010856A (enExample) |
| MY (1) | MY173567A (enExample) |
| PE (2) | PE20170125A1 (enExample) |
| PH (3) | PH12016501646B1 (enExample) |
| PL (2) | PL3125934T3 (enExample) |
| PT (2) | PT3241561T (enExample) |
| RU (2) | RU2744046C2 (enExample) |
| SG (3) | SG11201606583VA (enExample) |
| WO (1) | WO2015132598A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11982672B2 (en) | 2014-03-05 | 2024-05-14 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| EP3868388A1 (en) * | 2014-10-03 | 2021-08-25 | Oxford University Innovation Limited | Analysis of t-cell monotypia |
| CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Ltd | Protein-based t-cell receptor knockdown |
| CN110352068A (zh) | 2016-12-02 | 2019-10-18 | 南加利福尼亚大学 | 合成的免疫受体及其使用方法 |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| CN110402255B (zh) * | 2017-04-04 | 2022-12-02 | 豪夫迈·罗氏有限公司 | 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子 |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| WO2019025800A1 (en) * | 2017-08-02 | 2019-02-07 | Autolus Limited | CELLS EXPRESSING A CHIMERIC ANTIGENIC RECEPTOR OR A MANIPULATED TCR AND COMPRISING A SELECTIVELY EXPRESSED SELECTIVE NUCLEOTIDE SEQUENCE |
| IL311488A (en) * | 2017-08-23 | 2024-05-01 | Dragonfly Therapeutics Inc | Proteins that bind D2NKG, 16CD, and tumor-associated antigen |
| WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| WO2019129851A1 (en) | 2017-12-29 | 2019-07-04 | Cellectis | Method for improving production of car t cells |
| GB201800298D0 (en) * | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| US12215154B2 (en) | 2018-01-19 | 2025-02-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting γδ T cells with chimeric antigen receptors |
| MX2020008333A (es) | 2018-02-08 | 2020-09-21 | Dragonfly Therapeutics Inc | Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales. |
| CA3090244A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| CN112119093A (zh) | 2018-02-20 | 2020-12-22 | 蜻蜓治疗公司 | 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法 |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| WO2020010229A1 (en) * | 2018-07-06 | 2020-01-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Car t cell therapy to target t cell specific cancers |
| WO2020018708A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
| GB201812650D0 (en) * | 2018-08-03 | 2018-09-19 | Autolus Ltd | Molecular assessment of TRBC usage |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CA3108427A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| CN113164570B (zh) | 2018-08-08 | 2024-05-14 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和肿瘤相关抗原的蛋白质 |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| GB201817822D0 (en) * | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| WO2020156335A1 (zh) * | 2019-01-29 | 2020-08-06 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
| AU2020226893B2 (en) * | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス，インコーポレーテッド | ＮＫｐ３０に結合する抗体分子およびその使用 |
| WO2020172598A1 (en) * | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| CN110317266A (zh) * | 2019-07-17 | 2019-10-11 | 东北农业大学 | 三种scFv抗体、其编码基因及其在制备治疗或预防O型口蹄疫病制剂中的应用 |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4121518A4 (en) * | 2020-03-16 | 2024-06-19 | Marengo Therapeutics, Inc. | MODIFIED CELL COMPOSITIONS AND METHODS OF USE |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| EP4132962A1 (en) | 2020-04-09 | 2023-02-15 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| AU2021261420A1 (en) * | 2020-04-24 | 2022-12-01 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| AU2021268340A1 (en) | 2020-05-06 | 2022-12-08 | Dragonfly Therapeutics, Inc. | Proteins binding NKG2D, CD16 and CLEC12A |
| CN111537735A (zh) * | 2020-05-15 | 2020-08-14 | 江西赛基生物技术有限公司 | 抗体检测试剂盒以及在免疫分析方面的应用 |
| CN111549044B (zh) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | 靶向trbc1 car-t细胞的制备方法与应用 |
| US12173318B2 (en) | 2020-08-18 | 2024-12-24 | Medigene Immunotherapies Gmbh | Enrichment of T cells using an anti-Cß antibody |
| CA3190573A1 (en) * | 2020-08-26 | 2022-03-03 | Andreas Loew | Methods of detecting trbc1 or trbc2 |
| WO2022177889A1 (en) * | 2021-02-17 | 2022-08-25 | The Johns Hopkins University | Methods and materials for treating clonal t cell expansions |
| US20220267415A1 (en) * | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| EP4301774A4 (en) | 2021-03-03 | 2025-08-13 | Dragonfly Therapeutics Inc | METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN |
| GB202112923D0 (en) * | 2021-09-10 | 2021-10-27 | Ucl Business Ltd | Binding domain |
| CN120076829A (zh) | 2022-10-18 | 2025-05-30 | 明治制果药业株式会社 | T细胞肿瘤的治疗剂 |
| WO2024236163A1 (en) | 2023-05-17 | 2024-11-21 | Morphosys Ag | T cell receptor beta constant region 2 (trbc2) antibodies |
| WO2024256823A1 (en) | 2023-06-14 | 2024-12-19 | Autolus Limited | Treatment of trbc1-positive t cell malignancies |
| JP2026524330A (ja) * | 2023-06-28 | 2026-07-22 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Ｔｒｂｃ標的化抗体薬物複合体 |
| GB202310981D0 (en) | 2023-07-18 | 2023-08-30 | Autolus Ltd | Method |
| IL326971A (en) * | 2023-09-05 | 2026-05-01 | Michele Pitaro | Single-chain variable fragment and molecules derived therefrom that bind the trvb5-1 fragment of the β chain of the human T-cell receptor |
| WO2025096673A1 (en) * | 2023-10-30 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions comprising cells targeting cancer and methods of using the same |
| WO2025202622A1 (en) * | 2024-03-26 | 2025-10-02 | Oxford University Innovation Limited | Antibodies |
| CN121299112B (zh) * | 2024-09-12 | 2026-04-17 | 中国食品药品检定研究院 | 一种检测九型hpv疫苗或抗原原液体外相对效力的方法 |
| WO2026060284A1 (en) * | 2024-09-13 | 2026-03-19 | The Johns Hopkins University | T cell receptor chain-targeted bispecific immune effector cell engaging antibodies for treating autoimmune diseases |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR930701620A (ko) * | 1990-08-09 | 1993-06-12 | 프레드릭 에이. 란길레 | 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법 |
| US6790604B1 (en) * | 1998-05-12 | 2004-09-14 | Stefan A. Cohen | Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells |
| AU2003233197A1 (en) * | 2002-04-29 | 2003-11-17 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| RU2355703C2 (ru) * | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Одноцепочечные рекомбинантные т-клеточные рецепторы |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
| WO2009151628A2 (en) * | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| US20130089554A1 (en) * | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| JP6000507B2 (ja) * | 2010-09-30 | 2016-09-28 | パナソニックヘルスケアホールディングス株式会社 | 診療情報登録装置 |
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| CN104395344B (zh) | 2012-05-07 | 2019-08-13 | 达特茅斯大学理事会 | 抗b7-h6抗体、融合蛋白及其使用方法 |
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| US10443100B2 (en) * | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| US20160081314A1 (en) * | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| EP3868388A1 (en) * | 2014-10-03 | 2021-08-25 | Oxford University Innovation Limited | Analysis of t-cell monotypia |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
-
2015
- 2015-03-05 RU RU2016138421A patent/RU2744046C2/ru active
- 2015-03-05 IL IL278879A patent/IL278879B2/en unknown
- 2015-03-05 SG SG11201606583VA patent/SG11201606583VA/en unknown
- 2015-03-05 ES ES17172755T patent/ES3033286T3/es active Active
- 2015-03-05 BR BR112016020304-6A patent/BR112016020304B1/pt active IP Right Grant
- 2015-03-05 ES ES15709319T patent/ES2758173T3/es active Active
- 2015-03-05 IL IL278878A patent/IL278878B/en unknown
- 2015-03-05 DK DK15709319.6T patent/DK3125934T3/da active
- 2015-03-05 PL PL15709319T patent/PL3125934T3/pl unknown
- 2015-03-05 KR KR1020167027423A patent/KR102088082B1/ko active Active
- 2015-03-05 FI FIEP17172755.5T patent/FI3241561T3/fi active
- 2015-03-05 PH PH1/2016/501646A patent/PH12016501646B1/en unknown
- 2015-03-05 PE PE2016001548A patent/PE20170125A1/es unknown
- 2015-03-05 WO PCT/GB2015/050643 patent/WO2015132598A1/en not_active Ceased
- 2015-03-05 MY MYPI2016703188A patent/MY173567A/en unknown
- 2015-03-05 HU HUE17172755A patent/HUE071755T2/hu unknown
- 2015-03-05 EP EP25222920.8A patent/EP4736887A3/en active Pending
- 2015-03-05 PL PL17172755.5T patent/PL3241561T3/pl unknown
- 2015-03-05 SG SG10201906460PA patent/SG10201906460PA/en unknown
- 2015-03-05 DK DK17172755.5T patent/DK3241561T3/da active
- 2015-03-05 MX MX2016010856A patent/MX2016010856A/es active IP Right Grant
- 2015-03-05 CA CA2940564A patent/CA2940564C/en active Active
- 2015-03-05 KR KR1020207006444A patent/KR102235201B1/ko active Active
- 2015-03-05 SG SG10201906461SA patent/SG10201906461SA/en unknown
- 2015-03-05 HU HUE15709319A patent/HUE047641T2/hu unknown
- 2015-03-05 US US15/123,287 patent/US20170066827A1/en not_active Abandoned
- 2015-03-05 JP JP2016554603A patent/JP6767872B2/ja active Active
- 2015-03-05 AU AU2015225944A patent/AU2015225944B2/en active Active
- 2015-03-05 EP EP15709319.6A patent/EP3125934B1/en active Active
- 2015-03-05 CN CN202410891896.0A patent/CN118852462A/zh active Pending
- 2015-03-05 PT PT171727555T patent/PT3241561T/pt unknown
- 2015-03-05 EP EP25172928.1A patent/EP4610654A3/en active Pending
- 2015-03-05 CN CN202010859460.5A patent/CN112094353A/zh active Pending
- 2015-03-05 CN CN202010858243.4A patent/CN112094347A/zh active Pending
- 2015-03-05 EP EP17172755.5A patent/EP3241561B1/en active Active
- 2015-03-05 CN CN201580011306.XA patent/CN106068276B/zh active Active
- 2015-03-05 KR KR1020207006445A patent/KR102235202B1/ko active Active
- 2015-03-05 PH PH1/2020/550202A patent/PH12020550202B1/en unknown
- 2015-03-05 RU RU2021101502A patent/RU2021101502A/ru unknown
- 2015-03-05 PT PT157093196T patent/PT3125934T/pt unknown
- 2015-03-05 PE PE2021000759A patent/PE20211887A1/es unknown
- 2015-03-05 CU CU2016000129A patent/CU24475B1/es unknown
-
2016
- 2016-08-04 IL IL247110A patent/IL247110A0/en active IP Right Grant
- 2016-08-19 MX MX2019013845A patent/MX2019013845A/es unknown
- 2016-08-19 MX MX2019013846A patent/MX2019013846A/es unknown
- 2016-09-01 CL CL2016002195A patent/CL2016002195A1/es unknown
-
2017
- 2017-05-26 US US15/606,480 patent/US20170334998A1/en not_active Abandoned
- 2017-05-31 JP JP2017107689A patent/JP6767931B2/ja active Active
-
2018
- 2018-10-30 CL CL2018003096A patent/CL2018003096A1/es unknown
-
2019
- 2019-06-07 CL CL2019001568A patent/CL2019001568A1/es unknown
- 2019-06-07 CL CL2019001567A patent/CL2019001567A1/es unknown
- 2019-07-09 AU AU2019204925A patent/AU2019204925B2/en active Active
- 2019-07-09 AU AU2019204921A patent/AU2019204921C1/en active Active
-
2020
- 2020-03-25 JP JP2020054667A patent/JP7149304B2/ja active Active
- 2020-04-01 PH PH12020550203A patent/PH12020550203A1/en unknown
-
2021
- 2021-09-15 JP JP2021150189A patent/JP2021184773A/ja not_active Withdrawn
-
2024
- 2024-04-03 JP JP2024060080A patent/JP2024074907A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016138421A (ru) | ХИМЕРНЫЙ АНТИГЕННЫЙ РЕЦЕПТОР (CAR) С АНТИГЕНСВЯЗЫВАЮЩИМИ ДОМЕНАМИ К КОНСТАНТНОЙ ОБЛАСТИ β Т-КЛЕТОЧНОГО РЕЦЕПТОРА | |
| Fischbach et al. | CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis | |
| Vogrig et al. | Pathophysiology of paraneoplastic and autoimmune encephalitis: genes, infections, and checkpoint inhibitors | |
| Oweida et al. | Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration | |
| Unterrainer et al. | PET/CT imaging for tumour response assessment to immunotherapy: current status and future directions | |
| AU2017266686B2 (en) | Markers selectively deregulated in tumor-infiltrating regulatory T cells | |
| Li et al. | CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice | |
| AU2025205213A1 (en) | Chimeric antigen receptor T cells targeting the tumor microenvironment | |
| JP2018508215A5 (enExample) | ||
| JP2020529830A5 (enExample) | ||
| JP2021522820A5 (enExample) | ||
| JP2020503891A5 (enExample) | ||
| JP2019519208A5 (enExample) | ||
| JP2016196468A5 (enExample) | ||
| JP2020527027A5 (enExample) | ||
| FI3332006T3 (fi) | Uusia anti-PD-L1-vasta-aineita | |
| JP2018518939A5 (enExample) | ||
| JP2022512882A5 (enExample) | ||
| JP2018536436A5 (enExample) | ||
| JP2018531014A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| Bugide et al. | Epigenetic mechanisms dictating eradication of cancer by natural killer cells | |
| JP2017513478A5 (enExample) | ||
| JP2018508475A5 (enExample) | ||
| WO2018102786A1 (en) | Methods for modulation of car-t cells |